Maximus Inc.

▲ Bull Case

• ◆AI-driven margin re-rating to 12.5% operating margin by FY2031 (vs. 10.5% FY2026 baseline) generates $17+ EPS, which at a re-rated 14-16x P/E delivers a $240-$280 share price scenario — a +280% potential return.
• ◆PACT Act + VA backlog sustains VES at high-single-digit revenue growth through at least FY2028; federal segment grows from ~$3.2B to $4.5B+ by FY2031, anchoring overall revenue at 7%+ CAGR.
• ◆Multiple normalization to peer median (~14x P/E) alone — without any operating outperformance — would take the stock to ~$117 (~+90% from current) on FY2026 EPS, since the gap between MMS and peer multiples is wider than fundamentals justify.

▼ Bear Case

• ◆Federal contract award delays of 12-18 months under DOGE policy uncertainty defer revenue from FY2027 into FY2029; combined with VES volume plateau as VA expands direct-hire capacity, US Federal revenue grows only 3% rather than 5-6%, holding EPS flat at $8.50-$9.00 through FY2028.
• ◆AI investments fail to yield 60-80bps of operating margin in the base case timeframe; margins stagnate at ~9.5%, removing the upside earnings vector and leaving the thesis dependent on multiple expansion alone.
• ◆Govcon sector remains de-rated through FY2027 as DOGE narrative persists; even with mechanical EPS growth from buybacks, MMS continues trading at 9-10x P/E, limiting upside to $75-$85 in a 24-month view — still positive but well below base-case expectations.

“The dominant Street debate is 'DOGE-discounted govcon trade or value trap?' Sell-side ratings cluster bullish (Stifel $95, Baird $92, William Blair $90, TD Cowen $88, JP Morgan $90) but two large houses (Deutsche Bank $75, Goldman $73) sit at hold/neutral with explicit policy-risk discounts. The buy-side debate is narrower: does the deleveraging-and-margin story compound through DOGE noise, or do federal procurement delays defer the thesis by 18-24 months? No major participant is structurally bearish — short interest is just 3-5% of float and declining. The setup is 'consensus mildly bullish, market price implying severe bear' — a divergence that typically resolves through either earnings beats triggering covering or sustained operating misses confirming the structural concerns.”

• ◆FY2026 Q3/Q4 earnings beats (Aug-Oct 2026) confirming margin expansion trajectory and PACT Act-driven VES revenue durability.
• ◆Capital return policy update — first dividend increase since 2020 expected within next 12 months; potential buyback authorization upsize.
• ◆Material federal contract win ($200M+ TCV) demonstrating that DOGE policy is not impeding new awards on essential program administration.
• ◆AI/automation milestone announcement — concrete margin-impact disclosure (e.g., 'X% reduction in average handle time generated $Y of EBITDA in FY2026') at FY2027 Investor Day.
• ◆DOGE narrative inflection — federal budget cycle clarity (FY2027 budget passage in Q1 2026) removing procurement-timing overhang on the sector.
• ◆VES contract recompete confirmation — successful renewal of major VES task orders validating the long-duration thesis.

• ◆Medicaid block grant legislation advancing in Congress (low probability ~10-15%, but high impact) would structurally reduce US Services revenue 15-22%.
• ◆VA insourcing of VES — VA expanding direct-hire clinical capacity could reduce VES volumes 20-30% over 3 years, costing ~$300M revenue and $40-60M EBITDA.
• ◆Cybersecurity breach (repeat of MOVEit-scale): legal/remediation costs $50-100M plus potential contract risk on $200-400M of revenue, plus 1-2 multiple turn de-rating.
• ◆Major contract loss at re-compete (>$300M TCV) on VES, Medicare appeals, or a large state Medicaid eligibility contract — invalidates the moat thesis and triggers multiple compression.
• ◆Margin guidance cut below 9% signaling AI investments dilutive without payback — removes the central upside vector.
• ◆Labor cost re-acceleration if wage inflation returns; ~70-75% of COGS is labor.